Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Groundhog Day -- Ignore unavailable to you. Want to Upgrade?

To: Augustus Gloop who wrote (3657)	5/7/2002 4:09:25 PM
From: GraceZ	Read Replies (1) \| Respond to of 6346

I'm married to a guy with no butt. His legs just end in a crack. He claims I have more than enough to make up for both of us.

To: Augustus Gloop who wrote (3657)	5/8/2002 9:06:55 AM
From: Perry Ganz	Read Replies (1) \| Respond to of 6346

Anyone need drugs BRL does generic, Ya Know the ones your insurance covers Great report this A.M. Reuters Company News Barr Labs third-quarter profit jumps POMONA, N.Y., May 8 (Reuters) - Generic drugmaker Barr Laboratories Inc. said on Wednesday its fiscal third-quarter profit rose sharply, but revenue growth slowed from the prior quarter on increased competition for Barr's generic version of antidepressant Prozac. Pomona, New York-based Barr (NYSE:BRL - news) posted earnings of $53.1 million, or $1.17 per share in the fiscal third quarter ending March 31, compared with $18.1 million, or 40 cents per share, a year ago. Analyst estimates ranged from 80 cents to 88 cents per share, with an average forecast of 83 cents per share, according to Thomson Financial/First Call. Total revenues for the third quarter of fiscal 2002 climbed to $261.4 million, a gain of 64 percent over total revenues of $159.8 million for the same period last year, but down markedly from the $366 million in sales in the second quarter. Barr last year won the right to be the only seller of certain generic forms of Prozac, originally made by Eli Lilly and Co. (NYSE:LLY - news), for six months. But the six months expired at the end of January and other copycats flooded the market, eroding Barr's sales of the drug. At support stockcharts.com[h,a]daclyyay[dd][pb50!b200!f][vc60][iUb14!La12,26,9]&pref=G Perry